hVIVO (FRA:CRO) Short-Term Debt : €0.00 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is hVIVO Short-Term Debt?

hVIVO's Short-Term Debt for the quarter that ended in Dec. 2023 was €0.00 Mil.

hVIVO's annual Short-Term Debt declined from Dec. 2021 (€0.35 Mil) to Dec. 2022 (€0.00 Mil) but then stayed the same from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).

hVIVO Short-Term Debt Historical Data

The historical data trend for hVIVO's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

hVIVO Short-Term Debt Chart

hVIVO Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

2.01

0.40

0.35

hVIVO Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Short-Term Debt	Get a 7-Day Free Trial															0.35	0.10	-	-	-

hVIVO Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

hVIVO Short-Term Debt Related Terms

Thank you for viewing the detailed overview of hVIVO's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

hVIVO (FRA:CRO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » hVIVO PLC (FRA:CRO) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

OPORF:USA HVO:Ireland ORPH:UK HVO:UK

Address

42, New Road, Queen Mary Bioenterprises Innovation Centre, London, GBR, E1 2AX

Website

https://www.hvivo.com

hVIVO PLC is a European-focused, rare, and orphan drug consulting services platform. The principal activity of the Group is that of a rapidly growing specialist CRO pharmaceutical services company, which involves the testing of vaccines and antivirals using human-challenge clinical trials. The group is also engaged in Venn Life Sciences' Clinical Research Division, providing a suite of consulting and clinical trial services to pharmaceutical, biotechnology, and medical device organizations.

hVIVO (FRA:CRO) Headlines

No Headlines